Plenary Presentations From the 2019 ASH Annual Meeting & Exposition

On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.